Industry & policyReview

Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement

Fig. 1. The EASO Integration Framework for incretin-based therapies. — Fig. 1. The EASO Integration Framework for incretin-based therapies.The EASO Integration Framework for incretin-based therapies.Correia et al.

The Lancet Regional Health Europe

The paper

Jorge César Correia, Jennifer L. Baker, Emma Boyland,

Luca Busetto, Ľubomíra Fábryová, Tryggvi Helgason, Paolo Sbraccia, Euan Woodward, Volkan Yumuk,

University of Geneva

The Lancet Regional Health Europe · 3 Sep 2026

doi.org/10.1016/j.lanepe.2026.101840 PubMed 42733510

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026